Board of Trustees
Appointed to the Board: May 2016
Julian is the global head of the Natural Resources Group at Bank of America Merrill Lynch and responsible for development of the firm’s business in the oil, gas, mining, power and renewables sectors globally. He joined Bank of America Merrill Lynch in 2010 after over two decades at Citigroup.
Julian and his wife Fiona are parents to five children, all of whom were born prematurely at Chelsea and Westminster Hospital. Two are autistic and one has cerebral palsy.
The Mylchreests were Founding Donors of Borne, and have personally funded and helped grow the music therapy department at Chelsea and Westminster Hospital over several years. Julian is also a member of the Chelsea and Westminster Hospital Development Board.
Previous trustee roles have included serving as a trustee of the children’s communication charity, I Can, and as a board member of Create, an arts and music charity for the disadvantaged and disabled.
Appointed to the Board: May 2016
Nick is founder and owner of George & Dragon, a leading independent advertising agency based in Soho with clients including HM Government, Daily Mail, Mail on Sunday, NHS England, Kwik Fit, Scope and London HIV Prevention. Nick began his career at Saatchi & Saatchi, where he became Joint Managing Director before co-founding M&C Saatchi where he was Joint Chief Executive before becoming Chairman of M&C Saatchi Europe. He is also the non-executive Chairman of The Groucho Club. Nick’s expertise is invaluable as we continue to build our brand and reputation. Nick helps us navigate our way through marketing and advertising decisions, and is a strong advocate for Borne.
He and his wife Elvira have four naughty children.
Trustee and Chair of Borne’s Scientific Advisory Committee
Appointed to the Board: October 2017
Tom MacDonald is Professor of Immunology at Bart’s and the London School of Medicine and Dentistry, Queen Mary, University of London. He is a co-investigator on a Medical Research Council (“MRC”) Programme working to develop new molecules to treat inflammatory bowel disease.
Tom received a PhD in immunology from Glasgow in 1976, before completing his post-doc at the Trudeau Institute in upstate New York. Since then he has worked at Jefferson Medical College in Philadelphia as an Associate Professor, at Merck and Co and at Bart’s Medical College where he was appointed a Wellcome Trust Senior Lecturer, promoted to reader and given a personal chair at the University of London.
In 2000, he headed up the Division of Infection, Inflammation and Repair at Southampton Medical School before returning to Bart’s and The London in 2005 as Professor of Immunology and Dean for Research in the Medical and Dental School. He now has over 400 publications, mostly on how inappropriate immune reactions cause disease in the human gut. His h-index is 86 with almost 26,000 citations. He was awarded FRCPath in 1995 and FMedSci in 2002 and elected a fellow of the Academy of Medical Sciences in 2002. In 2008, he received the President’s Medal from the British Society of Gastroenterology.
Tom’s notable achievements include identifying that T cells cause coeliac disease and Crohn’s disease; the role of TNF-alpha in Irritable Bowel Disease; developing ModulenIBD to treat pediatric Crohn’s disease; and identifying the critical role of Smad7 in chronic inflammation in Crohn’s disease. Additionally, he was a former associate editor of Gut and Gastroenterology and the IBD journal. He has served on many grant awarding panels and advisory groups and was a member of the review panel of NC3R’s (2011-16), Action Medical Research (2011-16), was a past member of PSMB at MRC (2007-11) and chaired the MRC non-clinical training panel (2012-16), sat on the MRC training and careers panel ( 2012-16), currently chairs the Mason Medical Foundation Awards panel and also chairs the Kings Health Partners Awards Panel. He currently serves on the oversight group of the EMINENT initiative at MRC.
Appointed to the Board: May 2016
Charlotte is Managing Partner of Albyns, a property development and investment business based in London. She holds several business Directorships, and was Director of Conferences at Euromoney Institutional Investor plc, where she was responsible for the firm’s events business.
Charlotte also supports inclusive theatre company, Chickenshed, which brings together children from all abilities and backgrounds to perform inspiring drama.
Charlotte chairs Borne’s Events Committee and is a key driver of support for Borne’s fundraising through a group of dedicated volunteers, many of whom have been touched by the effects of prematurity and want to help raise funds for future generations of families.
Charlotte and her husband Andrew actively support Borne as an expression of sincere gratitude to Professor Mark Johnson, who made a profound difference to their son’s premature start in life. It is their wish to ensure that many more mothers, babies and their families could benefit from the vital research led by Mark to prevent preterm birth.
Appointed to the Board: October 2017
Hetty leads the Global Industrial and Infrastructure Services practice at leading global search and assessment firm, Russell Reynolds Associates. She advises clients on board succession and development, working with quoted, private and private equity backed companies. Hetty joined Russell Reynolds in 2004, having previously worked at Whitehead Mann (now part of Korn Ferry) as a Consultant in their Board Practice, leading executive and non-executive director search projects.Hetty received her M.A. in modern history from Brasenose College, Oxford University.
Hetty and her husband Nick are longstanding supporters of Borne’s quest to understand and prevent preterm birth. They live in London with their two children who were born prematurely. Their lives were touched by tragedy with the stillbirth of Freddie at 37 weeks. Nick climbed Mount Kilimanjaro as a member of Borne’s challenge team in 2015.
Francesco Vanni d’Archirafi
Appointed to the Board : October 2017
Francesco is the former CEO of Citi Holdings and now Vice Chairman for Citi EMEA. Francesco began his career with Citi in 1983, and has held many senior roles with the group including Global Co-Head for Mergers and Acquisitions, Country Corporate Officer for Spain, Chairman and CEO of Citibank International plc, and CEO of Citi Transaction Services.
Francesco serves on the Boards of the Citi Foundation, CitiFinancial Credit Company, Associates First Capital Corporation, PEFCO (Private Export Funding Corporation), Mapfre International S.A. and Business in the Community (BiTC), where he is the Vice Chair of BiTC’s International Leadership Team. In addition, Francesco serves on the International Advisory Board of IESE, the Advisory Council for The Kogod School of Business at American University and the Advisory Board of the Vatican Foundation Centesimus Annus Pro Pontifice. He is the Chairman of Junior Achievement Worldwide, a member of its Board of Governors, and a Board member of Junior Achievement-Young Enterprise Europe.
Francesco is a finance graduate of the American University in Washington, D.C., where he received the Stanley I. Posner Award as the graduating senior with the highest overall academic average. He obtained his M.B.A. in finance and international business from Columbia University in 1983.
We benefit from Francesco’s extensive financial knowledge, ideas and experience. He injects passion to the cause and continues to challenge us to raise the bar on our ambition. Francesco and his wife Charlotte are Founding Donors of Borne and have two growing girls.
Professor Mark Johnson
Founder and Chief Scientific Officer
As Borne’s Founder and Chief Scientific Officer, Mark has responsibility for framing and delivering the science strategy of the respective programmes of research undertaken at Borne. He is the Research Director responsible for bringing all research proposals and updates to the Scientific Advisory Committee for independent appraisal, and is accountable to the Board for the measurement and transparent reporting of progress and impact at regular intervals.
Mark is also the Clinical Chair in Obstetrics at Imperial College, and Director of Research and Consultant Obstetrician at the Chelsea and Westminster Hospital focusing on high risk maternity care. Mark began his research early in his career. His PhD, supported by The William’s Fellowship from the University of London, defined the role of relaxin in human pregnancy and was awarded in 1995.
Clinically, Mark initially trained in general medicine, endocrinology and diabetes, specialising in reproductive endocrinology. He set up the highly successful IVF unit in Chelsea and Westminster Hospital. He later trained in Obstetrics and Gynaecology, becoming the only dually accredited Consultant in General Medicine and Obstetrics and Gynaecology in the UK, following which he became the Professor in Clinical Obstetrics at Imperial College in 2010.
Mei Li Powell
Chief Operating Officer
Mei Li is Borne’s Chief Operating Officer responsible for the financial health and resource management of Borne, and ensuring operational and project delivery to the highest standards in line with its values and mission. Mei Li is also responsible for coordinating a proactive programme of income generation, managing fundraising, donor relationships and overseeing associated donor stewardship programmes as Borne charts a course for growth.
Before joining Borne in May 2017, Mei Li held senior roles in banking and wealth management over the last 27 years where she led and developed global teams as chief marketing officer, business development director and managing director of corporate communications, investor relations and marketing. Mei Li brings a complementary set of skills and experience to Borne, where she is working in close partnership with visionary expert Professor Mark Johnson to provide operational leadership and ensure the success of Borne’s strategies, plans and research programmes.
I have joined Borne at a very exciting time. As a mother blessed with two healthy children, I am passionate about Borne’s work and intend to play a proactive role in supporting our scientists in their quest for answers to detect, treat and care for women at risk of delivering their babies too early.